Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course

• Published in: The Journal of pediatrics Vol. 209; pp. 92 - 96.e1
• Main Authors: Deneau, Mark, Perito, Emily, Ricciuto, Amanda, Gupta, Nitika, Kamath, Binita M., Palle, Sirish, Vitola, Bernadette, Smolka, Vratislav, Ferrari, Federica, Amir, Achiya Z., Miloh, Tamir, Papadopoulou, Alexandra, Mohan, Parvathi, Mack, Cara, Kolho, Kaija-Leena, Iorio, Raffaele, El-Matary, Wael, Venkat, Veena, Chan, Albert, Saubermann, Lawrence, Valentino, Pamela L., Shah, Uzma, Miethke, Alexander, Lin, Henry, Jensen, M.K.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019
• Subjects: Adolescent; Analysis of Variance; autoimmune; Biomarkers - blood; Child; Cholangitis, Sclerosing - blood; Cholangitis, Sclerosing - drug therapy; cholestasis; Cohort Studies; Female; Follow-Up Studies; gamma-Glutamyltransferase - blood; Humans; juvenile; Liver Function Tests; Male; Predictive Value of Tests; Retrospective Studies; Severity of Illness Index; surrogate endpoint; Time Factors; treatment; Treatment Failure; Treatment Outcome; Ursodeoxycholic Acid - therapeutic use; treatment; PSC; AST; autoimmune; cholestasis; GGT; APRI; juvenile; IBD; UDCA; surrogate endpoint
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/j.jpeds.2019.01.039

To investigate patient factors predictive of gamma glutamyltransferase (GGT) normalization following ursodeoxycholic acid (UDCA) therapy in children with primary sclerosing cholangitis. We retrospectively reviewed patient records at 46 centers. We included patients with a baseline serum GGT level ≥50 IU/L at diagnosis of primary sclerosing cholangitis who initiated UDCA therapy within 1 month and continued therapy for at least 1 year. We defined “normalization” as a GGT level <50 IU/L without experiencing portal hypertensive or dominant stricture events, liver transplantation, or death during the first year. We identified 263 patients, median age 12.1 years at diagnosis, treated with UDCA at a median dose of 15 mg/kg/d. Normalization occurred in 46%. Patients with normalization had a lower prevalence of Crohn's disease, lower total bilirubin level, lower aspartate aminotransferase to platelet ratio index, greater platelet count, and greater serum albumin level at diagnosis. The 5-year survival with native liver was 99% in those patients who achieved normalization vs 77% in those who did not. Less than one-half of the patients treated with UDCA have a complete GGT normalization in the first year after diagnosis, but this subset of patients has a favorable 5-year outcome. Normalization is less likely in patients with a Crohn's disease phenotype or a laboratory profile suggestive of more advanced hepatobiliary fibrosis. Patients who do not achieve normalization could reasonably stop UDCA, as they are likely not receiving clinical benefit. Alternative treatments with improved efficacy are needed, particularly for patients with already-advanced disease.